Info: Read More
  • 中药标准品生产商,产品定制服务
  • 美迪紫檀素

    Medicarpin

    美迪紫檀素
    产品编号 CFN98411
    CAS编号 32383-76-9
    分子式 = 分子量 C16H14O4 = 270.3
    产品纯度 >=98%
    物理属性 Powder
    化合物类型 Flavonoids
    植物来源 The herbs of Hedysarum polybotrys Hand. -Mazz.
    ChemFaces的产品在影响因子大于5的优秀和顶级科学期刊中被引用
    提供自定义包装
    产品名称 产品编号 CAS编号 包装 QQ客服
    美迪紫檀素 CFN98411 32383-76-9 1mg QQ客服:2159513211
    美迪紫檀素 CFN98411 32383-76-9 5mg QQ客服:2159513211
    美迪紫檀素 CFN98411 32383-76-9 10mg QQ客服:2159513211
    美迪紫檀素 CFN98411 32383-76-9 20mg QQ客服:2159513211
    存储与注意事项
    1. 在您收到产品后请检查产品。如无问题,请将产品存入冰霜并且样品瓶保持密封,产品可以存放长达24个月(2-8摄氏度)。

    2. 只要有可能,产品溶解后,您应该在同一天应用于您的实验。 但是,如果您需要提前做预实验,或者需要全部溶解,我们建议您将溶液以等分试样的形式存放在-20℃的密封小瓶中。 通常,这些可用于长达两周。 使用前,打开样品瓶前,我们建议您将产品平衡至室温至少1小时。

    3. 需要更多关于溶解度,使用和处理的建议? 请发送电子邮件至:service@chemfaces.com
    订购流程
  • 1. 在线订购
  • 请联系我们QQ客服

  • 2. 电话订购
  • 请拨打电话:
    027-84237683 或 027-84237783

  • 3. 邮件或传真订购
  • 发送电子邮件到: manager@chemfaces.com 或
    发送传真到:027-84254680

  • 提供订购信息
  • 为了方便客户的订购,请需要订购ChemFaces产品的客户,在下单的时候请提供下列信息,以供我们快速为您建立发货信息。
  •  
  • 1. 产品编号(CAS No.或产品名称)
  • 2. 发货地址
  • 3. 联系方法 (联系人,电话)
  • 4. 开票抬头 (如果需要发票的客户)
  • 5. 发票地址(发货地址与发票地址不同)
  • 发货时间
    1. 付款方式为100%预付款客户,我们将在确认收到货款后当天或1-3个工作日发货。

    2. 付款方式为月结的客户,我们承诺在收到订单后当天或1-3个工作日内发货。

    3. 如果客户所需要的产品,需要重新生产,我们有权告知客户,交货时间需要延期。
    ChemFaces的产品在许多优秀和顶级科学期刊中被引用

    Cell. 2018 Jan 11;172(1-2):249-261.e12.
    doi: 10.1016/j.cell.2017.12.019.
    IF=36.216(2019)

    PMID: 29328914

    Cell Metab. 2020 Mar 3;31(3):534-548.e5.
    doi: 10.1016/j.cmet.2020.01.002.
    IF=22.415(2019)

    PMID: 32004475

    Mol Cell. 2017 Nov 16;68(4):673-685.e6.
    doi: 10.1016/j.molcel.2017.10.022.
    IF=14.548(2019)

    PMID: 29149595

    ACS Nano. 2018 Apr 24;12(4): 3385-3396.
    doi: 10.1021/acsnano.7b08969.
    IF=13.903(2019)

    PMID: 29553709

    Nature Plants. 2016 Dec 22;3: 16206.
    doi: 10.1038/nplants.2016.205.
    IF=13.297(2019)

    PMID: 28005066

    Sci Adv. 2018 Oct 24;4(10): eaat6994.
    doi: 10.1126/sciadv.aat6994.
    IF=12.804(2019)

    PMID: 30417089
    我们的产品现已经出口到下面的研究机构与大学,并且还在增涨
  • Osmania University (India)
  • Tohoku University (Japan)
  • Universitas Airlangga (Indonesia)
  • University of Hull (United Kingdom)
  • CSIRO - Agriculture Flagship (Australia)
  • University of Minnesota (USA)
  • Shanghai Institute of Biochemistry and Cell Biology (China)
  • University of Virginia (USA)
  • University of Toulouse (France)
  • University of Canterbury (New Zealand)
  • University of Vienna (Austria)
  • Kyushu University (Japan)
  • University of Liège (Belgium)
  • Universita' Degli Studi Di Cagliari (Italy)
  • More...
  • 国外学术期刊发表的引用ChemFaces产品的部分文献
  • Oncology Letters2018, 4690-4696
  • Eur J Pharmacol.2023, 951:175770.
  • Food Chem.2023, 424:136383.
  • The Journal of Animal & Plant Sciences.2020, 30(6):1366-1373
  • Molecules.2023, 28(8):3503.
  • Mediators Inflamm.2016, 2016:7216912
  • Molecules.2019, 24(2):E343
  • Cancer Lett. 2023, 18:216584.
  • Biochem Pharmacol.2020, 178:114083
  • Int J Mol Sci.2023, 24(24):17589.
  • Food Funct.2022, doi: 10.1039
  • Eur J Pharmacol.2024, 963:176280.
  • Arch Toxicol.2024, 98(5):1415-1436.
  • Food Bioscience2024, 57:103518.
  • Pharmaceuticals (Basel).2021, 14(10):1046.
  • Anticancer Res.2022, 42(9):4403-4410.
  • J Chromatogr B Analyt Technol Biomed Life Sci.2021, 1187:123012.
  • BMC Complement Altern Med.2018, 18(1):221
  • Molecules.2019, 24(9):E1719
  • Research Square2020, doi: 10.21203.
  • Molecules.2020, 25(7):1625.
  • Separations2021, 8(7),90.
  • Int J Mol Sci.2020, 21(7):2530.
  • ...
  • 生物活性
    Description: Medicarpin, a legume phytoalexin, acts as an estrogen receptor (ER) agonist, can stimulate osteoblast differentiation likely via ERβ, promote achievement of peak bone mass, and is devoid of uterine estrogenicity; in addition, given its excellent oral bioavailability, it can be potential osteogenic agent. Medicarpin sensitizes myeloid leukemia cells to TRAIL-induced apoptosis through the induction of DR5 and activation of the ROS-JNK-CHOP pathway. Medicarpin also has antifungal activity.
    Targets: ROS | JNK | Bcl-2/Bax | TNF-α | NF-kB | p65 | P450 (e.g. CYP17) | CHOP
    In vitro:
    Environ Sci Pollut Res Int. 2014 Dec;21(24):14091-8.
    Effect of lead treatment on medicarpin accumulation and on the gene expression of key enzymes involved in medicarpin biosynthesis in Medicago sativa L.[Pubmed: 25053287]
    Lead (Pb) is the most common heavy metal contaminant in the environment. The present study was undertaken to determine the effect of Pb treatment on medicarpin production and accumulation in Medicago sativa L.
    METHODS AND RESULTS:
    To this aim, 7- and 30-day-old plants were treated with 0, 120, 240, 500, and 1,000 μM Pb during 10 days. The content of medicarpin was determined by HPLC, and the extent of medicarpin production was deduced from the result of semiquantitative RT-PCR performed on PAL, CHS, and VR genes. HPLC results indicated that medicarpin concentration has been reduced in the roots, while its exudation to the culture medium has been increased. RT-PCR results indicated that the transcript levels of PAL, CHS, and VR genes have not been affected following Pb stress in seedlings. At the vegetative stage, transcript levels of PAL and CHS genes have been reduced in the roots. However, the transcript level of VR gene increased at 120 and 240 μM Pb, while it decreased at higher concentrations. In the shoot, the transcript levels of PAL, CHS, and VR genes were increased following increased concentration of lead in the medium.
    CONCLUSIONS:
    Overall, q-PCR results suggest that medicarpin biosynthesis has been induced in the shoots and reduced in the roots of the plants treated with a toxic concentration of Pb.
    Pharmacology. 1985;31(5):289-93.
    Specificity of medicarpin and related isoflavonoids in inhibition of rat hepatic mixed function oxidase activity.[Pubmed: 3877941]
    The cytochromes P-450 of the mixed function oxidase system metabolize a wide variety of endogenous compounds to either nontoxic products or toxic metabolites. A number of natural products, such as flavonoids, influence this metabolism. Exposure to these compounds may therefore be a factor in animal and human responsiveness to cytochrome P-450 substrates.
    METHODS AND RESULTS:
    We have examined the effect of the pterocarpan Medicarpin on the cytochrome P-450-dependent aryl hydrocarbon hydroxylase (AHH) and ethoxycoumarin deethylase (ECD) activities of rat liver microsomes. Medicarpin and maackiain and two of their biosynthetic precursors inhibit the constitutive and phenobarbital (PB)-induced types of AHH, but have little effect on the 3-methylcholanthrene (MC)-induced type of AHH. This is in contrast to the effect of the commonly used cytochrome P-450 inhibitor 7,8-benzoflavone, which inhibits the hepatic AHH of MC-treated rats and has no effects on the AHH of control or PB-treated rats. However, Medicarpin inhibited the constitutive as well as the PB- and MC-induced ECD.
    CONCLUSIONS:
    The specific modulatory effect as well as its relative availability suggests the utility of Medicarpin as a probe for different forms of cytochrome P-450 in animal tissues.
    Phytomedicine . 2015 Dec 1;22(13):1186-94.
    Medicarpin and millepurpan, two flavonoids isolated from Medicago sativa, induce apoptosis and overcome multidrug resistance in leukemia P388 cells[Pubmed: 26598918]
    Abstract Background: High consumption of flavonoids has been associated with a decrease risk of cancer. Alfalfa (Medicago sativa) leaves have been widely used in traditional medicine and is currently used as a dietary supplement because of their high nutrient content. We previously reported the cytotoxic activity of alfalfa leaf extracts against several sensitive and multidrug resistant tumor cell lines. Hypothesis/purpose: We aimed to determine whether medicarpin and millepurpan, two isoflavonoids isolated from alfalfa leaves, may have pro-apoptotic effects against drug-sensitive (P388) and multidrug resistant P388 leukemia cells (P388/DOX). Study design/methods: Cells were incubated with medicarpin or millepurpan for the appropriate time. Cell viability was assessed by the MTT assay. DNA fragmentation was analyzed by agarose gel electrophoresis. Cell cycle analysis was realized by flow cytometry technics. Caspases 3 and 9 activities were measured using Promega caspACE assay kits. Proteins and genes expression were visualized respectively by western-blot using specific antibodies and RT-PCR assay. Results: P-glycoprotein-expressing P388/DOX cells did not show resistance to medicarpin (IC50 ≈ 90 μM for P388 and P388/DOX cells) and millepurpan (IC50 = 54 μM and 69 μM for P388 and P388/DOX cells, respectively). Treatment with medicarpin or millepurpan triggered apoptosis in sensitive as well as multidrug resistant P388 cells. These effects were mediated through the mitochondrial pathway by modifying the balance pro/anti-apoptotic proteins. While 3 μM doxorubicin alone could not induce cell death in P388/DOX cells, concomitant treatment with doxorubicin and subtoxic concentration of medicarpin or millepurpan restored the pro-apoptotic cascade. Each compound increased sensitivity of P388/DOX cells to doxorubicin whereas they had no effect in sensitive P388 cells. Vinblastine cytotoxicity was also enhanced in P388/DOX cells (IC50 = 210 nM to 23 and 25 nM with medicarpin and millepurpan, respectively). This improved sensitivity was mediated by an increased uptake of doxorubicin in P388/DOX cells expressing P-gp. P-gp expression was not altered by exposure to medicarpin and millepurpan. Conclusion: These data indicate that medicarpin and millepurpan possess pro-apoptotic properties and potentiate the cytotoxicity of chemotherapy drugs in multidrug resistant P388 leukemia cells by modulating P-gp-mediated efflux of drugs. These flavonoids may be used as chemopreventive agents or as sensitizer to enhance cytotoxicity of chemotherapy drugs in multidrug resistant cancer cells. Keywords: Alfalfa; Apoptosis; Flavonoids; Medicarpin; Millepurpan; Multidrug resistance.
    In vivo:
    Mol Cell Endocrinol. 2010 Aug 30;325(1-2):101-9.
    Medicarpin inhibits osteoclastogenesis and has nonestrogenic bone conserving effect in ovariectomized mice.[Pubmed: 20570709]
    Medicarpin, a pterocarpan class of naturally occurring benzopyran furanobenzene compound was synthesized in gram scale to investigate its effects on murine bone cells and in ovariectomized (OVx) mice.
    METHODS AND RESULTS:
    1 Medicarpin, at as low as 10(-10)M suppressed osteoclastogenesis in bone marrow cells (BMCs). Medicarpin-induced apoptosis of mature osteoclasts isolated from long bones. Effects of Medicarpin in osteoclasts appear to be independent of estrogen receptor (ER) activation as ICI 180,782 failed to abrogate its effects on osteoclasts. In calvarial osteoblasts, Medicarpin (10(-10)M) blocked nuclear factor kappaB (NF-kappaB) signaling assessed by tumor necrosis factor alpha (TNFalpha)-stimulated nuclear translocation of p65 subunit of NF-kappaB. Medicarpin also inhibited the expression of TNFalpha in mouse calvarial osteoblasts. This effect was ER dependent as ICI 180,782 reversed the suppressive effect of Medicarpin on TNFalpha mRNA levels in osteoblasts. In addition, like 17beta-estradiol, presence of Medicarpin inhibited TNFalpha-induced upregulation of interleukin-1, and -6 mRNA levels in osteoblasts. In co-cultures consisting of calvarial osteoblasts and BMCs, presence of Medicarpin increased osteoprotegerin (OPG)/receptor activator of NF-kappaB ligand (RANKL) ratio and reduced mRNA levels of osteoclast markers including tartrate-resistant acid phosphatase and RANK. OVx mice administered Medicarpin (10.0mgkg(-1)day(-1)) orally for 30days had reduced formation of osteoclasts but increased formation of osteoprogenitor cells in BMCs compared with OVx+vehicle group. Medicarpin treatment to OVx mice maintained parameters of trabecular microarchitecure. Medicarpin exhibited no uterine estrogenicity.
    CONCLUSIONS:
    Our findings point towards direct and indirect inhibitory effects of Medicarpin on osteoclastogenesis in vitro that contribute to its bone sparing effect in OVx mice.
    制备储备液(仅供参考)
    1 mg 5 mg 10 mg 20 mg 25 mg
    1 mM 3.6996 mL 18.498 mL 36.9959 mL 73.9919 mL 92.4898 mL
    5 mM 0.7399 mL 3.6996 mL 7.3992 mL 14.7984 mL 18.498 mL
    10 mM 0.37 mL 1.8498 mL 3.6996 mL 7.3992 mL 9.249 mL
    50 mM 0.074 mL 0.37 mL 0.7399 mL 1.4798 mL 1.8498 mL
    100 mM 0.037 mL 0.185 mL 0.37 mL 0.7399 mL 0.9249 mL
    * Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
    部分图片展示
    产品名称 产品编号 CAS编号 分子式 = 分子量 位单 联系QQ
    3-羟基-9,10-二甲氧基紫檀烷; Methylnissolin CFN90838 73340-41-7 C17H16O5 = 300.3 10mg QQ客服:215959384
    美迪紫檀苷; Methylnissolin-3-O-glucoside CFN93199 94367-42-7 C23H26O10 = 462.5 20mg QQ客服:215959384
    3-Hydroxy-8,9-methylenedioxypterocarpene; 3-Hydroxy-8,9-methylenedioxypterocarpene CFN96063 59901-98-3 C16H10O5 = 282.3 5mg QQ客服:1457312923
    马卡因; 高丽槐素; Maackiain CFN99746 19908-48-6 C16H12O5 = 284.27 20mg QQ客服:215959384
    红车轴草根甙; 三叶豆紫檀苷; Trifolirhizin CFN97160 6807-83-6 C22H22O10 = 446.4 20mg QQ客服:1457312923
    6alpha-羟基高丽槐素; 6alpha-Hydroxymaackiain CFN96037 61218-44-8 C16H12O6 = 300.3 5mg QQ客服:1457312923
    豌豆素; Pisatin CFN96000 20186-22-5 C17H14O6 = 314.3 5mg QQ客服:2159513211
    Sophoracarpan A ; Sophoracarpan A CFN96672 1674359-82-0 C17H16O5 = 300.31 5mg QQ客服:2159513211
    Sophoracarpan B ; Sophoracarpan B CFN96671 1674359-84-2 C17H14O6 = 314.30 5mg QQ客服:215959384
    Meliotocarpan D; Meliotocarpan D CFN95401 83013-81-4 C17H16O6 = 316.3 5mg QQ客服:1457312923

    信息支持


    公司简介
    订购流程
    付款方式
    退换货政策

    ChemFaces提供的产品仅用于科学研究使用,不用于诊断或治疗程序。

    联系方式


    电机:027-84237783
    传真:027-84254680
    在线QQ: 1413575084
    E-Mail:manager@chemfaces.com

    湖北省武汉沌口经济技术开区车城南路83号1号楼第三层厂房


    ChemFaces为科学家,科研人员与企业提供快速的产品递送。我们通过瑞士SGS ISO 9001:2008质量体系认证天然化合物与对照品的研发和生产